3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholanylamine | 1470023-29-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholanylamine
• 英文别名: (3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-17-[(2R)-4-aminobutan-2-yl]-6-ethyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
• CAS: 1470023-29-0
• 化学式: C₂₅H₄₅NO₂
• 分子量: 391.638
• InChiKey: UHTWCKDYARKJBV-APIYUPOTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholanylamine 生成
  参考文献：
  名称：

  PROCESS FOR PREPARATION OF SULFONYLUREA BILE ACID DERIVATIVES

  摘要：

  本发明涉及制备化合物I的方法，或其在药学上可接受的盐或溶剂。这些化合物和药物组合物可用作FXR或TGR5调节剂。具体来说，本发明涉及胆酸衍生物及其制备和使用方法。本发明涉及一种制备化合物(II)及其盐和衍生物的方法，这些化合物是合成生物活性分子的有用中间体，特别是在合成FXR和TGR5调节剂方面。本发明还涉及一种制备化合物(III)及其二乙胺盐的方法。

  公开号：

  US20180148469A1
• 作为产物：
  描述：

  奥贝胆酸 在 氯化亚砜 、 sodium azide 、 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholanylamine
  参考文献：
  名称：

  Probing the Binding Site of Bile Acids in TGR5

  摘要：

  TGR5 is a G-protein-coupled receptor (GPCR) mediating cellular responses to bile acids (BAs). Although some efforts have been devoted to generate homology models of TGR5 and draw structure-activity relationships of BAs, none of these studies has hitherto described how BAs bind to TGR5. Here, we present an integrated computational, chemical, and biological approach that has been instrumental to determine the binding mode of BAs to TGR5. As a result, key residues have been identified that are involved in mediating the binding of BAs to the receptor. Collectively, these results provide new hints to design potent and selective TGR5 agonists.

  DOI：

  10.1021/ml400247k

文献信息

• Process for preparation of sulfonylurea bile acid derivatives
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US10947264B2

  公开（公告）日：2021-03-16

  The present invention relates to compounds of Formulas 3-6, where R4 PG1 and PG2 are defined as disclosed herein. These compounds are useful as intermediates in processes for preparing a compound of Formula I: where R1 is defined as disclosed herein.

  本发明涉及式 3-6 的化合物、 其中 R4 PG1 和 PG2 的定义如本文所述。这些化合物在制备式 I 化合物的工艺中可用作中间体： 其中 R1 的定义如本文所述。
• Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160176917A1

  公开（公告）日：2016-06-23

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
• BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160185815A1

  公开（公告）日：2016-06-30

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
• [EN] PROCESS FOR PREPARATION OF SULFONYLUREA BILE ACID DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS DE TYPE ACIDE BILIAIRE DE LA FAMILLE DES SULFONYLURÉES
  申请人：ENANTA PHARM INC

  公开号：WO2018102418A1

  公开（公告）日：2018-06-07

  The present invention relates to processes for preparing a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.